AB1536 MYCOPHENOLATE MOFETIL VERSUS RITUXIMAB IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE ASSOCIAT...
AB1536 MYCOPHENOLATE MOFETIL VERSUS RITUXIMAB IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
About this item
Full title
Author / Creator
Navarro Joven, C. , Alonso de Francisco, M. , Machattou, M. , Navarro Palomo, P. , Martínez Rodado, A. , Ramos Ortiz de Zarate, L. , Merino Argumánez, C. , García Magallón, B. , Rusinovich Lovgach, O. , Godoy, H. , Fernandez Castro, M. , Isasi Zaragoza, C. , Barbadillo, C. , Sanz, J. , Andreu Sánchez, J. L. and Campos Esteban, J.
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
Background:Interstitial lung disease (ILD) is a well-known and severe systemic complication of numerous rheumatologic diseases. The management of these entities is still under study, being both mofetil mycophenolate (MMF) and rituximab (RTX) therapeutic alternatives used in routine clinical practice.Objectives:To compare the effectiveness of mycoph...
Alternative Titles
Full title
AB1536 MYCOPHENOLATE MOFETIL VERSUS RITUXIMAB IN THE TREATMENT OF INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_3100503706
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_3100503706
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2024-eular.5676
